tootsie's blog

Transcatheter Aortic Valve Implantation (TAVI) Market: Trends, Forecast, and Competitive Analysis to 2031

tootsie's photo
tootsie
·

4 min read

Executive Summary

The Transcatheter Aortic Valve Implantation (TAVI) market research reports indicate that the market is projected to grow at a compound annual growth rate (CAGR) of % during the forecasted period. TAVI is a minimally invasive procedure for patients with severe aortic stenosis and is gaining traction due to its less invasive nature compared to traditional open-heart surgery.

Market trends in the TAVI industry include increasing prevalence of aortic valve disorders, rising adoption of minimally invasive procedures, technological advancements in devices, and growing elderly population globally. The demand for TAVI procedures is expected to increase as patients seek safer and more effective treatment options.

The geographical spread of the TAVI market includes North America, Asia-Pacific (APAC), Europe, USA, and China. North America currently holds the largest market share due to well-established healthcare infrastructure, favorable reimbursement policies, and increasing adoption of innovative medical technologies. APAC is anticipated to witness significant growth due to the rising geriatric population and increasing awareness about minimally invasive procedures.

Europe is a key market for TAVI, driven by advancements in medical technology, increasing healthcare expenditure, and growing prevalence of cardiovascular diseases. The USA is also a significant market for TAVI procedures, driven by technological advancements, favorable reimbursement policies, and increasing adoption of minimally invasive procedures.

China is expected to emerge as a lucrative market for TAVI due to the growing healthcare infrastructure, rising prevalence of cardiovascular diseases, and increasing investments in medical research and development.

Overall, the Transcatheter Aortic Valve Implantation (TAVI) market is poised for significant growth in the coming years, driven by technological advancements, increasing prevalence of aortic valve disorders, and rising demand for minimally invasive procedures.

Get a Sample PDF of the Report: https://www.reliableresearchreports.com/enquiry/request-sample/917248

Market Segmentation:

This Transcatheter Aortic Valve Implantation (TAVI) Market is further classified into Overview, Deployment, Application, and Region. 

In terms of Components, Transcatheter Aortic Valve Implantation (TAVI) Market is segmented into:

  • Edwards Lifesciences
  • Medtronic
  • Abbott
  • Boston Scientific
  • Meril Life Sciences

https://www.reliableresearchreports.com/transcatheter-aortic-valve-implantation-tavi--r917248

The Transcatheter Aortic Valve Implantation (TAVI) Market Analysis by types is segmented into:

  • Transfemoral Approach
  • Transapical Approach
  • Others

Get a Sample PDF of the Report: https://www.reliableresearchreports.com/enquiry/request-sample/917248

The Transcatheter Aortic Valve Implantation (TAVI) Market Industry Research by Application is segmented into:

  • Aortic Stenosis
  • Aortic Regurgitation
  • Others

In terms of Region, the Transcatheter Aortic Valve Implantation (TAVI) Market Players available by Region are:

North America:

  • United States
  • Canada

Europe:

  • Germany
  • France
  • U.K.
  • Italy
  • Russia

Asia-Pacific:

  • China
  • Japan
  • South Korea
  • India
  • Australia
  • China Taiwan
  • Indonesia
  • Thailand
  • Malaysia

Latin America:

  • Mexico
  • Brazil
  • Argentina Korea
  • Colombia

Middle East & Africa:

  • Turkey
  • Saudi
  • Arabia
  • UAE
  • Korea

Purchase this Report: https://www.reliableresearchreports.com/purchase/917248

Key Drivers and Barriers in the Transcatheter Aortic Valve Implantation (TAVI) Market

Key drivers in the TAVI market include an increasing aging population, rising prevalence of aortic valve diseases, technological advancements in minimally invasive procedures, and growing adoption of TAVI over traditional open-heart surgery. However, barriers such as high cost of the procedure, limited reimbursement policies, lack of skilled healthcare professionals, and stringent regulatory approvals hinder the market growth.

Challenges faced in the TAVI market include the need for long-term clinical data to establish the safety and efficacy of TAVI procedures, ongoing debates regarding the optimal patient selection criteria, potential complications associated with TAVI such as stroke and paravalvular leakage, and the need for continuous innovation to improve patient outcomes and reduce healthcare costs.

Inquire or Share Your Questions If Any Before Purchasing This Report: https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/917248

Competitive Landscape

Edwards Lifesciences is a pioneer in the field of cardiovascular medical devices and is a key player in the TAVI market. The company developed the first transcatheter heart valve, SAPIEN, which was approved by the FDA in 2011. Since then, Edwards Lifesciences has continued to innovate and improve its TAVI technology, leading to significant market growth and dominance.

Medtronic, a global leader in medical technology, is another major player in the TAVI market. The company's CoreValve system has been widely adopted by healthcare providers around the world. Medtronic has a strong presence in the TAVI market and continues to invest in research and development to enhance its product offerings.

Abbott, Boston Scientific, and Meril Life Sciences are also significant players in the TAVI market. These companies have developed innovative TAVI technologies and have made significant contributions to the advancement of minimally invasive heart valve replacement procedures.

The TAVI market is expected to experience robust growth in the coming years, driven by an aging population and increasing prevalence of heart valve diseases. According to a market research report, the global TAVI market was valued at $ billion in 2020 and is projected to reach $5.8 billion by 2027, with a compound annual growth rate of 10.9%.

In terms of sales revenue, Edwards Lifesciences reported revenue of $4.4 billion in 2020, with a significant portion contributed by its TAVI products. Medtronic reported revenue of $30.1 billion in the same year, with its CoreValve system being a key revenue driver in the structural heart segment. Abbott, Boston Scientific, and Meril Life Sciences also reported strong sales revenue from their respective TAVI product offerings.

Purchase this Report: https://www.reliableresearchreports.com/purchase/917248

Get a Sample PDF of the Report: https://www.reliableresearchreports.com/enquiry/request-sample/917248

 

Check more reports on reliableresearchreports.com